Urinary and Sexual Outcomes in Long-Term (5+years) Prostate Cancer Disease Free Survivors After Radical Prostatectomy

Gacci, Mauro; Simonato, A.; Varca, Virginia; Romagnoli, Andrea; Ambruosi, Carlo; Venzano, Fabio; Esposito, Marco; Montanaro, T.; Masieri, Lorenzo; Lanciotti, Michele; Mantella, Annalisa; Rossetti, M; Serni, Sergio; Carmignani, G.; Carini, Marco

doi:10.1016/s0022-5347(09)61634-7

Cited by 11 publications

(15 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The current study found that SB was associated with age at diagnosis of prostate cancer, marital status and time of assessment since surgery. Other studies have noted similar findings [22,23] and additional associations. Within the CaPSURE database, a study of post prostatectomy men found that those with a high school education or less were more likely to have worse SB then men who were college graduates [10].…”

Section: Discussionsupporting

confidence: 68%

Among potent men post radical prostatectomy, does the need for phosphodiesterase inhibitors have an impact on sexual bother scores?

et al. 2011

View full text Add to dashboard Cite

OBJECTIVE To determine whether the current definition of potency, inclusive of phosphodiesterase inhibitor (PDEi) use, is valid with respect to sexual bother (SB). This will be assessed by characterizing the effect of PDEi use on SB scores in men who are potent post radical prostatectomy. PATIENTS AND METHODS The study population consisted of patients who were potent both before and after radical prostatectomy, with at least 2 years of follow-up. Disease-specific quality of life data were evaluated by the University of California, Los Angeles, Prostate Cancer Index (PCI) survey. The relationships between changes in sexual function (SF) and SB and use of PDEi over time were evaluated by mixed model analysis controlling for age, clinical risk group, marital status, and time of PCI assessment. RESULTS Of the 246 patients who met the study criteria, 39% reported PDEi use at some point after treatment. PDEi use was not associated with improved SF (P = 0.81). Furthermore, PDEi use was not associated with a change in SB (P = 0.36). Both SF and SB were significantly associated with time of assessment and age, and SF and SB each improved over time. In addition, SB was significantly associated with marital status. CONCLUSION In this analysis, there was no difference in SF scores between men who were potent with or without the use of PDEi. Furthermore, there was no difference in SB scores between men who were potent with or without the use of PDEi. This suggests that the current, inclusive, definition of potency is valid with respect to SB.

show abstract

Section: Discussionsupporting

confidence: 68%

Among potent men post radical prostatectomy, does the need for phosphodiesterase inhibitors have an impact on sexual bother scores?

et al. 2011

View full text Add to dashboard Cite

show abstract

“…Because of the smaller sample size of married/partnered participants who completed the DAS measure, the relationship function models only included months of ADT, current sexual function, and sexual bother as independent variables. Those were chosen as the most relevant variables to include based on the literature and conceptual relations among study variables as well as our interest in evaluating the importance of sexual bother in the context of ADT‐related effects on sexual function [21,24,35]. To test whether sexual bother explained a significant amount of unique variance in each outcome, covariates and sexual function were included in step 1 and sexual bother was included in step 2.…”

Section: Methodsmentioning

confidence: 99%

“…Despite these significant physiologic changes, there may be variability in the degree to which men are bothered by ADT sexual side effects [21]. Although most research has been in localized prostate cancer, findings suggest sexual bother may be largely independent of sexual function and uniquely related to QOL outcomes [21–24]. Changes in sexual function occur within the context of other psychosocial and situational factors related to sexuality (e.g., expectations for sexual performance, perceptions of diminished masculinity, having an available partner, and partners' sexual function and interest [18,25,26]).…”

Section: Introductionmentioning

confidence: 99%

Sexual Bother in Men with Advanced Prostate Cancer Undergoing Androgen Deprivation Therapy

Benedict

Traeger

Dahn

et al. 2014

The Journal of Sexual Medicine

View full text Add to dashboard Cite

The majority of APC patients undergoing ADT will experience sexual dysfunction, but there is variability in their degree of sexual bother. Psychosocial aspects of sexual functioning should be considered when evaluating men's adjustment to ADT effects. Assessment of sexual bother may help identify men at risk for more general distress and lowered QOL. Psychosocial interventions targeting sexual bother may complement medical treatments for sexual dysfunction and be clinically relevant, particularly for younger men and those first starting ADT.

show abstract

“…P rostate cancer (PCa) is the most common non-cutaneous cancer diagnosed in American men [1]. Although 5-year survival rates among men treated for early stage disease approach 100% [1], the adverse impact of treatment on quality of life is a prominent concern and often a basis for treatment selection [2,3]. Men contend with a host of treatment-related complications, including declines in sexual, urinary, and bowel functioning [4].…”

Section: Introductionmentioning

confidence: 99%

Loss of Masculine Identity, Marital Affection, and Sexual Bother in Men with Localized Prostate Cancer

Zaider

Manne

Nelson

et al. 2012

The Journal of Sexual Medicine

View full text Add to dashboard Cite

Introduction Erectile dysfunction (ED) is one of the most frequent sources of distress after treatment for prostate cancer (PCa), yet evidence suggests that men do not easily adjust to loss of sexual function over time. A hypothesized determinant of men's adaptation to ED is the degree to which they experience a loss of masculine identity in the aftermath of PCa treatment. Aims The aims of this study were (i) to describe the prevalence of concerns related to diminished masculinity among men treated for localized PCa; (ii) to determine whether diminished masculinity is associated with sexual bother, after controlling for sexual functioning status; and (iii) to determine whether men's marital quality moderates the association between diminished masculinity and sexual bother. Methods We analyzed cross-sectional data provided by 75 men with localized PCa who were treated at one of two cancer centers. Data for this study were provided at a baseline assessment as part of their enrollment in a pilot trial of a couple-based intervention. Main Outcome Measures The sexual bother subscale from the Prostate Health-Related Quality-of-Life Questionnaire and the Masculine Self-Esteem and Marital Affection subscales from Clark et al's PCa-related quality-of-life scale. Results Approximately one-third of men felt they had lost a dimension of their masculinity following treatment. Diminished masculinity was the only significant, independent predictor of sexual bother, even after accounting for sexual functioning status. The association between diminished masculinity and sexual bother was strongest for men whose spouses perceived low marital affection. Conclusions Diminished masculinity is a prominent, yet understudied concern for PCa survivors. Regardless of functional status, men who perceive a loss of masculinity following treatment may be more likely to be distressed by their ED. Furthermore, its impact on adjustment in survivorship may rely on the quality of their intimate relationships.

show abstract

Urinary and Sexual Outcomes in Long-Term (5+years) Prostate Cancer Disease Free Survivors After Radical Prostatectomy

Abstract: Background: After long term disease free follow up (FUp) patients reconsider quality of life (QOL) outcomes. Aim of this study is assess QoL in prostate cancer patients who are disease-free at least 5 years after radical prostatectomy (RP).

Cited by 11 publications

References 15 publications

Among potent men post radical prostatectomy, does the need for phosphodiesterase inhibitors have an impact on sexual bother scores?

Among potent men post radical prostatectomy, does the need for phosphodiesterase inhibitors have an impact on sexual bother scores?

Sexual Bother in Men with Advanced Prostate Cancer Undergoing Androgen Deprivation Therapy

Loss of Masculine Identity, Marital Affection, and Sexual Bother in Men with Localized Prostate Cancer

Contact Info

Product

Resources

About